Second-line systemic therapy for metastatic colorectal cancer-Reference-Cited by-同舟云学术

Second-line systemic therapy for metastatic colorectal cancer

Published:2017-01-27 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Mocellin Simone¹²,Baretta Zora³,Roqué i Figuls Marta⁴,Solà Ivan⁵,Martin-Richard Marta⁶,Hallum Sara⁷,Bonfill Cosp Xavier⁴

Affiliation:

1. University of Padova; Department of Surgery, Oncology and Gastroenterology; Via Giustiniani 2 Padova Veneto Italy 35128

2. IOV-IRCCS; Istituto Oncologico Veneto; Padova Italy 35100

3. Ospedale di Montecchio; U.O.C. di Oncologia ULSS5 Ovest Vicentino; Montecchio Maggiore Vicenza Italy

4. CIBER Epidemiología y Salud Pública (CIBERESP); Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 171 Edifici Casa de Convalescència Barcelona Catalunya Spain 08041

5. CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona; Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 167 Pavilion 18 Barcelona Catalunya Spain 08025

6. Hospital de la Santa Creu i Sant Pau; Clinical Oncology; Sant Antoni Maria Claret 167 Barcelona Spain 08025

7. Cochrane; Cochrane Colorectal Cancer Group; 23 Bispebjerg Bakke Copenhagen Denmark DK 2400 NV

Publisher

Wiley

Subject

Pharmacology (medical)

Reference108 articles.

1. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study;Bendell;Clinical Colorectal Cancer,2013

2. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study;Bendell;Clinical Colorectal Cancer,2013

3. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial;Bennouna;Lancet Oncology,2013

4. A multicenter randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer;Cao;Medical Oncology,2015

5. Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis;Clarke;European Journal of Cancer,2011

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CircPDIA3/miR-449a/XBP1 feedback loop curbs pyroptosis by inhibiting palmitoylation of the GSDME-C domain to induce chemoresistance of colorectal cancer;Drug Resistance Updates;2024-09

2. Colorectal cancer associated with parathyroid hormone-related protein (review);Koloproktologia;2024-03-21

3. Mitotherapy prevents peripheral neuropathy induced by oxaliplatin in mice;Neuropharmacology;2024-03

4. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer;World Journal of Gastrointestinal Oncology;2023-11-15

5. An Activated Dendritic-Cell-Related Gene Signature Indicative of Disease Prognosis and Chemotherapy and Immunotherapy Response in Colon Cancer Patients;International Journal of Molecular Sciences;2023-11-03